Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „must“
Suchtreffer
Begriffe & Kennungen
Carmustine medac (previously Carmustine Obvius) · 4.5 · Melphalan Concomitant use with melphalan leads to increased risk of pulmonary toxicity.
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.5 · Phenytoin and dexamethasone In combination with chemotherapeutic medicinal products reduced activity of antiep
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 Undesirable effects · 1
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · * An increased risk for pulmonary toxicities upon treatment with conditioning regimes and HPCT for females has
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · 6 Very Myelosuppression. common
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · 7 Common Alopecia, flushing (due to alcohol content of solvent; increased with administration times <1-2 h), i
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · 8 Emetogenic potential The emetogenic potential is high at doses >250 mg/m2 and high to moderate in doses ≤250
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Blood and lymphatic system disorders
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Common Anaemia.
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Common Anorexia, constipation, diarrhoea, stomatitis. Hepatobiliary disorders Common Hepatotoxicity, reversibl
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Description of selected adverse reactions
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · MedDRA system organ Frequency Adverse reactions class Infections and infestations Not known Opportunistic infe
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Myelosuppression Myelosuppression is very common and begins 7-14 days of administration with recovery 42-56 da
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Neoplasms benign, Common Acute leukaemia, bone marrow malignant and unspecified dysplasia – following long-ter
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Nervous system disorders Very Ataxia, dizziness, headache. common Common Encephalopathy (high-dose therapy and
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Pulmonary fibrosis (with fatal outcome), pulmonary infiltration
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Pulmonary toxicity also manifested in the post-marketing phase as pneumonitis and interstitial lung disease. P
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Pulmonary toxicity has been observed in up to 30% of patients. In cases where pulmonary toxicity started early
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Rare Interstitial fibrosis (with lower doses). Gastrointestinal disorders Very Emetogenic potential. common Na
Eintrag öffnen